Allium Financial Advisors LLC Buys New Holdings in Aflac Incorporated (NYSE:AFL)

Key Points

• Allium Financial Advisors LLC has acquired a new stake in Aflac Incorporated, purchasing 2,502 shares valued at approximately $278,000 during the first quarter.
• Insider trading activity includes Director Joseph L. Moskowitz selling 1,000 shares, decreasing his ownership by 3.69%, while Masatoshi Koide sold 37,000 shares, representing a 34.26% reduction in his stake.
• Analysts have mixed views on Aflac, with the stock being downgraded from a "hold" to a "sell" rating, although several firms have raised their price targets, indicating a consensus target price of $108.15.

Allium Financial Advisors LLC acquired a new stake in Aflac Incorporated (NYSE:AFL - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,502 shares of the financial services provider's stock, valued at approximately $278,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC raised its position in shares of Aflac by 121.9% in the first quarter. Golden State Wealth Management LLC now owns 304 shares of the financial services provider's stock valued at $34,000 after buying an additional 167 shares in the last quarter. Garde Capital Inc. bought a new stake in Aflac during the first quarter valued at $36,000. Capital A Wealth Management LLC acquired a new stake in shares of Aflac in the 4th quarter valued at about $38,000. NBC Securities Inc. bought a new position in Aflac in the 1st quarter valued at about $44,000. Finally, JCIC Asset Management Inc. purchased a new stake in Aflac in the 1st quarter valued at about $44,000. Institutional investors own 67.44% of the company's stock.

Insiders Place Their Bets

In related news, Director Arthur Reginald Collins sold 2,750 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $105.70, for a total value of $290,675.00. Following the completion of the sale, the director owned 6,728 shares of the company's stock, valued at approximately $711,149.60. The trade was a 29.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joseph L. Moskowitz sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, May 8th. The stock was sold at an average price of $106.79, for a total value of $106,790.00. Following the completion of the sale, the director owned 26,096 shares of the company's stock, valued at approximately $2,786,791.84. This trade represents a 3.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,750 shares of company stock worth $4,304,295. Company insiders own 0.80% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Keefe, Bruyette & Woods boosted their price target on shares of Aflac from $104.00 to $106.00 and gave the company a "market perform" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. raised their price objective on shares of Aflac from $96.00 to $100.00 and gave the company a "neutral" rating in a research report on Tuesday, July 8th. Piper Sandler lifted their price target on shares of Aflac from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Wednesday, April 2nd. Morgan Stanley lifted their price target on shares of Aflac from $100.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Monday, May 19th. Finally, UBS Group boosted their price target on shares of Aflac from $109.00 to $114.00 and gave the company a "neutral" rating in a report on Wednesday, April 2nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $108.15.

Aflac Stock Down 1.3%

NYSE:AFL traded down $1.34 during trading hours on Wednesday, hitting $99.49. The stock had a trading volume of 804,964 shares, compared to its average volume of 2,110,834. Aflac Incorporated has a 1-year low of $94.87 and a 1-year high of $115.50. The company has a current ratio of 0.09, a quick ratio of 0.09 and a debt-to-equity ratio of 0.29. The company has a market cap of $53.79 billion, a PE ratio of 15.55, a price-to-earnings-growth ratio of 3.12 and a beta of 0.81. The business has a 50 day simple moving average of $102.83 and a two-hundred day simple moving average of $105.16.

Aflac (NYSE:AFL - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The financial services provider reported $1.66 earnings per share for the quarter, missing analysts' consensus estimates of $1.67 by ($0.01). The company had revenue of $3.40 billion for the quarter, compared to the consensus estimate of $4.53 billion. Aflac had a net margin of 21.27% and a return on equity of 15.55%. Aflac's revenue for the quarter was down 37.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.66 earnings per share. Analysts predict that Aflac Incorporated will post 6.88 EPS for the current year.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.